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Highly sensitive ligand-binding assays in
pre-clinical and clinical applications: immuno-PCR
and other emerging techniques
Mark Spengler,*a Michael Adlera and Christof M. Niemeyer*b
Recombinant DNA technology and corresponding innovations in molecular biology, chemistry and medi-
cine have led to novel therapeutic biomacromolecules as lead candidates in the pharmaceutical drug
development pipelines. While monoclonal antibodies and other proteins provide therapeutic potential
beyond the possibilities of small molecule drugs, the concomitant demand for supportive bioanalytical
sample testing creates multiple novel challenges. For example, intact macromolecules can usually not be
quantiﬁed by mass-spectrometry without enzymatic digestion and isotopically labeled internal standards
are costly and/or diﬃcult to prepare. Classical ELISA-type immunoassays, on the other hand, often lack
the sensitivity required to obtain pharmacokinetics of low dosed drugs or pharmacodynamics of suitable
biomarkers. Here we summarize emerging state-of-the-art ligand-binding assay technologies for
pharmaceutical sample testing, which reveal enhanced analytical sensitivity over classical ELISA formats.
We focus on immuno-PCR, which combines antibody speciﬁcity with the extremely sensitive detection of
a tethered DNA marker by quantitative PCR, and alternative nucleic acid–based technologies as well
as methods based on electrochemiluminescence or single-molecule counting. Using case studies, we
discuss advantages and drawbacks of these methods for preclinical and clinical sample testing.
1. Introduction
In recent years, therapeutic proteins and other macro-
molecules or conjugates thereof, such as toxins, enzymes,
monoclonal antibodies and antibody-drug-conjugates,1,2 have
gained an ever-increasing importance in pharmaceutical
research and corresponding drug development pipelines.3–7
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Examples of such “Biologics”, or generic variants thereof often
referred to as “biosimilars”,8,9 include therapeutic, mono-
clonal antibodies (mAbs),10–14 human blood clotting
factors,15,16 botulinum toxin,17 insulin,18 cellular growth
factors,19–23 and recombinant human cytokines.24–26 Owing to
their generally higher target specificity, such bulky biological
molecules provide novel therapeutic potentials, as compared
to classical small molecule drugs,27 such as the blockbusters
Fluticasone,28 Rosuvastine,29,30 or Aripiprazole.31 However, the
development of Biologics brings with it multiple challenges
when it comes to bioanalytical sample testing support for
tracing these compounds or quantifying the response of their
endogenous interaction partners.32–34 While quantification of
small-molecule drugs and metabolites can often be achieved
by mass spectrometry (MS)-based methods, these techniques
are usually not well suited for studying Biologics. Even though
MS techniques have made progress as means to analyze
macromolecules and to detect proteins in clinical settings,35
sensitivities are typically considerably above those of conven-
tional ligand-binding assays (LBA), which involve specific anti-
bodies and (enzymatic) signal amplification techniques.36,37 In
addition, most MS assays for clinical research also require anti-
body reagents to facilitate the detection of macromolecules,
thereby renouncing the main general advantage of MS, that is
the label-free detection of molecules-of-interest through their
absolute mass without the need for antibody interactions or
enzymatic activity.38–41
The well-established Enzyme-Linked-Immuno-Sorbent-
Assay (ELISA) technology, first described by Yalow et al.,42 is
considered the gold standard for LBAs. ELISA employs specific
binding of antibody reagents to the target of interest and the
subsequent signal amplification by enzymatic substrate con-
version enabling colorimetric or fluorimetric read-out (for a
schematic illustration, see Fig. 4a). The analytical sensitivity of
ELISA is limited by the linear nature of the enzymatic activity
upon conversion of one substrate molecule into one detectable
product molecule. In contrast, the so-called DNA-enhanced
LBAs usually employ polymerase-chain reaction (PCR)43 for
signal amplification, thus enabling the exponential amplifica-
tion of marker molecules. While the relatively young technol-
ogy of DNA-enhanced LBAs has previously been surveyed,44–52
we will here discuss this technology in the context of other
emerging techniques for high-sensitivity analyses of biomacro-
molecules with an emphasis on case studies from preclinical
and clinical sample testing in support of pharmaceutical drug
development programs.53 In this regard, “high sensitivity”
refers to an analytical sensitivity which is beyond that of com-
parable ELISA assays.54 Specifically, we discuss technology
platforms which have found their way into routine (pre)clinical
sample testing, DNA-enhanced immunoassays, electrochemi-
luminescence (ECL),55 single molecule counting (SMC)56 and a
brief selection of other emerging LBA technologies.57
2. General aspects
LBAs are used in a vast spectrum of applications ranging from
basic academic research to specific analytical and diagnostic
issues in clinical and pharmaceutical research and develop-
ment. Especially in vitro diagnostics (IVD) and pharmaceutical
sample testing have their own requirements to meet certain
specific regulations. In the following we will focus on consider-
ations for LBAs specific for the pharmaceutical industry.
Sample testing in support of drug development programs
requires not only consideration of various scientific and practi-
cal challenges. These include the expected needs for LBA’s
sensitivity and dynamic range, potential interferences with
endogenous components of the matrix, practical availability of
critical assay reagents – most prominently antibodies and
analyte standards -, available sample volumes, or specific
coordination of timelines (Fig. 1). In addition, the careful
attention of recommendations and guidelines on general LBA
method development and validation58–63 need to be taken into
account. For instance, the analytical assay range is defined by
accuracy and precision experiments of the standard curve and
quality control (QC) samples in a series of three to six indepen-
dent assay runs. Taking suitable curve fitting models into
account, the sensitivity of the assay’s upper and lower limit of
quantification (ULOQ, LLOQ, respectively) are defined as the
highest or lowest standard curve level that can be quantified
with acceptable accuracy (%RE = % relative error) and pre-
cision (CV% = % coeﬃcient of variation). Assay accuracy is
expressed as the relative error between a calculated and a
nominal concentration, while assay precision reflects the varia-
bility of concentration results in sample replication.61,62
In general, the recommended acceptance criteria diﬀeren-
tiate between pharmacokinetic (PK) studies to quantify drug
levels61 and biomarker studies to identify suitable markers
indicative for a disease or drug treatment. Biomarker quantifi-
cation is therefore mainly carried out in the discovery phase
(Fig. 1) to identify potential lead candidates and to gain
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pharmacodynamic (PD) information during later phases of the
drug development process. PD testing is usually implemented
in parallel to the mandatory PK sample testing, e.g. to monitor
the biological response to the drug’s therapeutic mecha-
nisms.62 Specifically, PK methods should meet fairly stringent
acceptance criteria for accuracy (%RE and CV% of ±20% with
±25% at the extremes of the analytical range at ULOQ and
LLOQ).61
In contrast, wider acceptance criteria can be applied for bio-
marker studies. Owing to the generally stronger matrix inter-
ference and potential endogenous background in biological
specimen, a scientifically reasonable “fit-for-purpose”
approach is possible here.62 Another key diﬀerence between
PK and biomarker assays usually concerns the availability of
an analyte standard. While the analyte in a PK assay, i.e., the
drug, is generally available as well-defined compound, bio-
marker assays typically require recombinant molecules to be
used as standards because the endogenous biomarker is either
extremely diﬃcult to obtain or not even accessible. The so-
called dilution linearity can then be tested to evaluate whether
samples with analyte concentrations above ULOQ can be
diluted to fit into the assay’s dynamic range. Due to relative
high sample concentrations needed, dilution linearity is
usually tested with spiked samples. Since the antibody
reagents may have diﬀerent binding characteristics for the arti-
ficial standard, which may diﬀer from the endogenous bio-
marker in e.g. post-translational modifications, the so-called
sample parallelism needs to be applied. There, the concen-
tration of the endogenous analyte, determined in a “real”,
individual biological sample by using a recombinant standard
in a standard curve matrix, is compared with concentration
values determined at various additional sample dilution ratios
over the MRD (minimum required dilution). This procedure is
done in order to prove that the endogenous analyte is quanti-
fied correctly in real samples despite any diﬀerences in
between study samples and the standard curve calibration
samples. While this sample parallelism represents an impor-
tant parameter in biomarker assay validation, it is usually not
relevant for PK assays.
Another important diﬀerence between PK and biomarker
studies stems from ethical and regulatory considerations. Due
to their availability from other sources, e.g. hospital remnant
samples, sample materials containing the analyte (endogenous
biomarker) can often be used for biomarker studies. However,
great care has to be taken here that the LBA’s signal response
is not aﬀected by diﬀerent populations, sampling procedures
or storage conditions of the control samples. In contrast,
samples already containing the analyte (drug) are usually not
available for PK assay development and validation at all.
Typical additional validation parameters like stability and
robustness of the assay, or specificity and selectivity in
diﬀerent specimen or study populations are addressed in the
regulatory guidelines of LBA method development.58–60 It is
important to note, that these only provide general guidance for
bioanalytical assay development, validation and sample
testing. They are often not strictly discriminating between
chromatography, mass-spectrometry or immunoanalytic tech-
niques, but mostly make suggestions regarding acceptance cri-
teria to be specifically defined for a given assay during assay
development and pre-validation. To specify guidance for
immunoassay technologies, the pharmaceutical and bioanaly-
tical community therefore usually publishes “white paper” rec-
ommendations for best practice procedures.61–63 However,
even these much more detailed descriptions do not cover all
relevant aspects of a given assay, in particular, when it comes
to specifications of emerging technologies, such as the here
described high sensitivity LBAs. Since the guidance for estab-
lished testing procedures can not always be directly transferred
to these novel techniques, it is of highest relevance to precisely
define and document assay limitations in order to meet the
typical validation criteria or at least to enable a scientifically
sound argumentation why the higher assay sensitivity requires
an adaptation of the common criteria.
In the following, we will briefly discuss some technical
issues of relevance for high sensitivity LBAs. Critical assay
Fig. 1 Key challenges for ligand-binding assays in the four develop-
ment phases of a macromolecular drug (biologic) from discovery of a
given compound for a particular therapeutic purpose over its pre-clini-
cal and clinical testing to drug approval by regulatory agencies and
beyond. The clinical phase is usually divided into three sub-phases I –
III. Phase I trials are usually conducted with small numbers of healthy
volunteers to determine drug safety and dosing. The main intention in
Phase II trials is to gain initial information on drug eﬃcacy and further
investigate safety in small patient numbers. Phase III trials determine
safety and eﬃcacy of the drug in larger patient populations, suﬃcient
for statistical evaluation. The main purposes of a given phase within the
development of a new drug are printed in italics. The associated main
challenges for the bioanalytical sample testing of each phase are indi-
cated in red. Note that biomarker quantiﬁcation is usually conducted in
the discovery phase to identify potential lead candidates and in parallel
to the mandatory PK sample testing during the following phases, e.g. to
monitor the biological response on the drug’s therapeutic mechanism.
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reagents include antibodies, aptamers or other oligonucleo-
tides, receptors, binding proteins, peptides or antigens, which
specifically recognize the analyte. The specificity and aﬃnity of
theses binders determine the performance of all LBAs.61,64–66
So-called signal generating reagents (SGR)67 are analyte-
binding molecules tagged to some sort of reporter, such as an
enzyme, a dye, fluorophore, or hapten group to enable down-
stream detection of the binding event. Notably, detection
technologies, which employ strong signal amplification have
advantages over amplification-free approaches because signal
amplification can compensate for low binding aﬃnities. For
example, it has been demonstrated that PCR-based signal
amplification enabled the use of weak binders which were not
well suited for conventional ELISA.68 The Signal-to-noise (S/N)
ratio reflects the intensity of specific signals with respect to
signals originating from negative controls. These background
signals typically stem from non-specific binding of SGR to
components of the sample matrix, other critical assay
reagents, buﬀer ingredients, or the surface of reaction vials or
beads. The optimization of the S/N ratio is of key importance
to warrant solid bioanalytical sample testing support (Fig. 2).
Because high sensitivity LBAs usually amplify specific and
non-specific binding events to a similar extent, increased sen-
sitivity not necessarily leads to a gain in S/N ratio.69,70
Reduction of background signals can be obtained by minimiz-
ation of non-specific SGR binding through careful choice of
reagents, extensive blocking, and, in some cases, by sample
dilution (see below).
Non-specific binding of assay reagents are minimized by
appropriate blocking reagents, used for coating surface
materials and spiking into buﬀers.45,66,71 For high-sensitivity
LBA, however, it is impossible to completely avoid background
signals. For example, in PCR-based LBA a single non-specifi-
cally bound DNA molecule is suﬃcient for generating a signifi-
cant level of background. This background signal needs to be
compensated by an increase in specific signals, which can be
obtained by tailored SGR with increased aﬃnity, such as anti-
body–DNA conjugates.66,72,73 Non-specific binding of SGR to
endogenous components present in the biological matrix of
the analyzed sample is a frequently encountered problem in
LBA development.74–76 Importantly, the composition and com-
plexity of the biological matrix often varies to a large extent
from, e.g., species to species, between diﬀerent study cohorts,
healthy to diseased individuals, or even between samples
drawn at diﬀerent time points from one individual. Reduction
of matrix eﬀects is therefore of paramount importance to meet
specificity and selectivity acceptance criteria. Specificity of the
assay is related to cross reactivity of the used antibodies
towards isoforms of the analyte or other structurally related
targets present in the matrix. Specificity can be validated by
spiking experiments using such interfering reagents if known
and available.61,62 Selectivity is referred to as the ability of the
assay to quantify the analytical target in the presence of other,
unknown sample intrinsic components that may be specific
for a certain subpopulation of the study or even disease
related. Selectivity is validated in spiking experiments in mul-
tiple lots (usually 10 or more) per relevant sample matrix sub-
population (e.g. healthy vs. diseased) and specificity and selec-
tivity are assessed for acceptable accuracy (%RE) and precision
(CV%) in the majority of tested samples (usually ≥80%).61
Negative influences of the biological matrix can be mini-
mized by dilution of samples under optimized buﬀer
Fig. 2 Schematic illustration of signal-to-noise (S/N) ratios of immunoassays arranged in the order of eﬃcacy for target detection (poor to best).
NC and PC represent arbitrary signal intensities for the negative and positive controls, respectively. Note that these are hypothetical test cases.
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conditions45,49,66,77–79 because dilution aﬀects low aﬃnity
interactions, i.e., the non-specific binding of assays reagents to
matrix components, to a greater extent than the high-aﬃnity
interactions between the SGR and the target. Hence, sample
dilution can lead to a significant increase in S/N ratio, pro-
vided that the read-out of the assay is suﬃcient to generate
clear signals even in the low concentration range. Moreover,
dilution brings with it the opportunity to adjust buﬀer con-
ditions with respect to pH, ion strength, concentration of
detergents and blocking reagents, or other factors which favor-
ably aﬀect the specific binding of SGR.80 The sample dilution
ratio, optimized with respect to assay accuracy and precision
using a specific diluent, is therefore often defined as “minimal
required dilution (MRD)” of the bioanalytical method.61,62
Signal amplification-based ultra-sensitive LBA technologies,
such as immuno-PCR (IPCR), allow for relative high sample
dilution ratios while still maintaining the required sensitivity
to support pharmacokinetic or pharmacodynamic studies
(Fig. 3).77,81–85
LBA development and validation guidelines58–62 rec-
ommend that the standard curve matrix should be identical or
as similar as possible to the study sample. This helps to com-
pensate for eﬀects interfering with antibody–analyte binding,
because the matrix interference is synchronized between
sample and standard curve performance.66,77 In the develop-
ment of PK methods to quantify exogenous drugs, quality
control (QC) samples must be prepared with the same type of
neat, unmodified matrix matching the study samples.61 In con-
trast, methods for assaying biomarkers62,63 can use standard
curve matrices and QC samples prepared in a substitute
matrix as long as this allows detection of the biomarker with
adequate accuracy and precision.62 The reason for this
recommendation is that endogenous biomarkers present in the
standard-curve matrix will limit the sensitivity of the method,
because SGR will specifically (!) bind to the endogenous
marker in standards and QCs. Therefore, a standard matrix
can be selected, which contains low concentrations of the bio-
marker, and this can be achieved, for instance, by stripping or
immune-depletion of pooled samples, or even biomarker-free
buﬀers.
2.1 Sample information density
Reduced sample consumption is of great importance in bio-
analytical sample testing support where available amounts are
of limited accessibility. This is the case in, e.g., small animal
studies, orphan studies, lumbar punctures, biopsies, or even
studies on the level of single cells. Macromolecule quantifi-
cation in support of microsampling studies, i.e., dried blood
spot sampling studies87 or studies restricted to very small
sample volumes,88 which aim for generation of, e.g., complete
PK-profiles from various time point blood samples derived
from the tail vein of a single mouse,89 are becoming increas-
ingly relevant.90 Obviously, it is desirable to extract as much
information as possible out of a given amount of sample.
While conventional ELISA testing typically requires approx.
50–100 µl sample volumes, amplification-based ultra-sensitive
technologies often need volumes of <5 µl.78,91 In addition to
providing high sensitivity in LBA microsampling studies, tol-
eration of high sample dilution also enables splitting of the
sample into several fractions, which can then be analyzed indi-
vidually to maximize the information density drawn from a
single sample. This approach has been termed as “polyplex-
ing” as a delineation to “multiplexing” where several analytical
targets are detected simultaneously in a single experiment.
Owing to spatially separated reactions, polyplexing avoids
typical problems of multiplex analyses, which stem from pro-
miscuous binding of SGR and non-specific cross-reaction
between multiple critical assay reagents. Challenges regarding
the selection of capture and detection antibodies increase
exponentially with growing numbers of targets in multiplex
assays.92–94 Hence, the selection of highly target specific and
non cross-reactive antibodies with comparable binding
eﬃciencies are the major obstacles of multiplex immuno-
assays. In contrast, polyplexing has been demonstrated as a
convenient strategy to avoid these problems because it com-
bines economic sample consumption and maximization of the
density of information which can be drawn from a single
sample.81–84
Fig. 3 The concentration of interfering matrix components in a test
sample is reduced by dilution, as schematically depicted in (A). Sample
dilution can lead to reduced negative matrix eﬀects and improved
analyte binding conditions, as exemplarily demonstrated in (B) for IPCR-
based detection of human interleukin 2 (IL-2). Note that signal response
is given in arbitrary units [a.u.] normalized by subtraction of non-spiked
negative controls. The error bars indicate the standard deviation
obtained from duplicate measurements. Data from ref. 86.
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3. Ultra-sensitive ligand biding assay
technologies
Due to the high specificity of antibody–antigen binding, assays
which employ antibodies as binding molecules play the major
role among the ligand-binding assays, with ELISA42,95 being
the gold standard for large molecule pre-clinical and clinical
bioanalytical sample testing support. In most ELISA variants, a
detector antibody is used as SGR, which specifically binds to
the target. Signal generation is usually achieved by an enzyme
linked to the antibody, which converts a silent precursor mole-
cule into a coloured, fluorescent or luminescent product in an
amplified fashion (Fig. 4a). To discriminate specific signals
from assay background originating from non-specifically
bound SGR or autoconversion of the precursor molecule,
antigen levels in the pM–µM range are usually needed to
become detectable at the macroscopic level. However, detec-
tion and quantification of molecular binding events is not
limited to ELISA-type enzymatic signal generation. Alternative
techniques based on chemical (ECL, Fig. 4b) or biochemical
amplification reactions (IPCR, Fig. 4c) have been developed,
which provide greater sensitivity than conventional ELISA
methods. Moreover, high-sensitivity read-out of LBA can be
achieved by techniques derived from single-molecule spectro-
scopy (single-molecule counting, SMC, see Fig. 5, below).
In this survey, we focus on methods, which are beyond the
level of proof-of-concept studies and have already found their
way into routine application, such that they have been evalu-
ated in pre-clinical and clinical studies of pharmaceutical
development. In particular, we will discuss amplified assays on
the basis of electrochemiluminescence (ECL) or nucleic acid
labels, i.e., IPCR, proximity ligation, and bead-based nucleic
acid biobarcodes, along with amplification-free assays based
on SMC. An overview of specific experimental details of these
technologies is given in Table 1. Before in depth discussion of
the aforementioned techniques along with related case
studies, we note that ECL (chapter 3.2) can be considered the
most established high-sensitvity LBA technology in pharma-
ceutical drug development, with a mayor vendor oﬀering com-
mercial equipment and kits. This technique has already been
reviewed extensively55,96–100 and we will therefore focus here
on selected recent case studies. Nanoparticle-based “Bio-
Barcode” technology (chapter 3.5) has also been reviewed
recently91 with an emphasis on diagnostic applications. The
fairly young technique of SMC (chapter 3.1) has so-far been
predominantly used for diagnostic purposes with a strong
focus on Troponin testing for cardiac infarction diagnosis.101
However, SMC is becoming more frequently used in pharma-
ceutically relevant sample testing support.57 Similar, IPCR is
gaining an increased significance for pharmaceutical develop-
ment processes (chapter 3.3), while the related nucleic acid-
enhanced proximity ligation currently appears to have an
emphasis on biomarker discovery (chapter 3.4).
3.1. Single-molecule counting
Single molecule counting (SMC) represents an LBA which
lacks any form of signal amplification but still holds the poten-
tial for increased sensitivity over standard ELISA.56 As outlined
in Fig. 5, samples are diluted in assay buﬀer and the target
molecule is allowed to bind to capture antibodies immobilized
either in microtiter plates or on magnetic microparticles. The
solid supports are washed and a fluorophore-labeled detection
antibody is allowed to bind to the immobilized immuno-
complex. Following to extensive washing to remove loosely
bound detection reagents, immunocomplexes are disrupted
with a protein denaturing elution buﬀer. The elution volume
is typically considerably smaller than the initial sample
volume, thereby increasing the concentration of the eluted
fluorophore-labeled detection antibody. In the case of particle-
based assay formats, samples are filtrated to remove particles
for downstream signal read-out. The eluate is analyzed in a
capillary flow cell through single molecule counting using an
automated confocal laser microscope. Photons emitted from
the fluorophore-labeled detection antibodies are counted in
defined time intervals, automatically evaluated and plotted as
individual peaks. These peaks represent digital yes/no infor-
mation rather than signal intensity. The number of peaks per
time interval allows one to calculate the concentration of
fluorophore-labeled detection antibody, which is then used to
Fig. 4 Schematic illustration of ampliﬁed LBA technologies, enzyme
linked immune sorbent assay (ELISA), electrochemiluninescence (ECL),
and Immuno-PCR (IPCR).
Fig. 5 Schematic illustration of single molecule counting (SMC) tech-
nology. 1: Solid-phase binding and separation of immunocomplex; 2:
transfer to single-ﬂuorescence detection cell and measurement; 3: ana-
lysis of signals above threshold “T” in a given time “t”.
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extrapolate the concentration of target antigen by aid of cali-
bration curves.
SMC technology typically leads to impressive assay sensi-
tivities and standard curve ranges. For instance, a greater than
4-log dynamic range from 60 pg ml−1 to 1 µg ml−1 was
reported for detection of human Cytokine IL-17.56 Numerous
publications relevant for pharmaceutical drug development,
mainly regarding heart muscle biomarker Cardiac Tropo-
nin102,105 but also human cytokines,106 suggest that SMC is
indeed emerging in pharmaceutical sample testing support.57
The fact that SMC immunoassays omit the need for enzymatic
signal amplification is often considered as an advantage
because no variations in enzymatic activity can occur which
would bias the analysis. However, minor diﬀerences in enzy-
matic activity in amplification-based techniques, such as
ELISA, ECL, or IPCR, are typically in an acceptable range. Like-
wise, variations in fluorophore-to-antibody labeling ratios,
which may lead to diﬀerences in fluorescence read-out in
SMC, seem to be controllable within the acceptable variations
in accuracy and precision for pharmaceutical sample
testing.58,60–62
However, the missing signal amplification step and the
related demand for suﬃciently high concentrations of analyte-
immunocomplexes in the sample (or else, suﬃcient sample
volumes to allow concentration of the analyte-immuno-
complexes by solid phase-based techniques) can limit the
scope of SMC. Sample dilution, which at the same time would
reduce sample consumption, is not always possible because of
the limited ability of SMC to tolerate higher sample dilution
ratios needed for minimization of interference from matrix
components (see section 2). These constraints can reduce options
to adjust assay performance in pooled matrices necessary for
analyzing individual samples from large patient cohorts,
which bring with them all the individual eﬀects that might
show up in a clinical trial.61–63 Biological specimen often have
to be filtered to ensure homogenous analyte-binding and fil-
tration has to be validated with the assay to control any poss-
ible bias introduced by this step. Moreover, the extensive
washing procedures needed to minimize signals from non-
specifically bound dye-labeled detection antibody as well as
potential interference from autofluorescent matrix com-
ponents and comparably long read-out time especially at low
analyte concentrations to collect the needed signals constitute
possible deficiencies of this technology.
It should be noted that additional amplification-free tech-
niques are currently emerging, which promise applicability in
real-life routine diagnostics and pharmaceutical sample
testing. These approaches include cantilever array-based label-
free sensing,107–109 microscale thermophoresis,110 acoustic
membrane micro particle (AMMP) technology,111 silicon
photonic microring resonators112–114 or optical fiber bundles
for single molecule detection and analysis.115–117 To the best
of our knowledge, however, these techniques have not yet been
exploited for routine support of pharmacological drug develop-
ment studies.
3.2. Electrochemiluminescence
Electrochemiluminescence (ECL) of tris(bipyridyl)ruthenium(II)
complexes is commonly used in immunoanalytics, clinical
diagnostics and also pharmaceutical drug development.55,96–100
ECL works similar as the conventional ELISA, however, the
signal amplification is facilitated by repeated oxidation and
Table 1 Overview of key aspects of the LBA technologies discussed in this review
Aspect
Technology
ELISA SMC ECL IPCR PLA/PEA Bio-Barcode
Detector label Enzyme Fluorophore Tris(bipyridyl)ruthenium(II) DNA-tag DNA-tag DNA-tag
Read-out Analog
Colorimetric/
Fluorometric
Digital & analog
(concentration
dependent)
Flow cytometry
Analog
Electrochemiluminescence
Analog
Real-time
qPCR
Analog
Hybridization/PCR/
RCA
Analog
Hybridization/
PCR
Signal
amplification
Enzymatic
turnover-
dependent
No Electrochemical Exponential Dependent on read-
out: None –
Exponential
Dependent on
read-out: None –
Exponential
Ligand-binding
conditions
Interphase
(plate)
Interphase (plate)
and Semi-
homogenous
(beads)
Interphase (plate) Interphase
(plate)
Homogenous
(surface
independent) and
Semi-homogenous
(beads)
Semi-
homogenous
(beads)
Sample volumea 100 µl 100 µl 100 µl 30 µl 30 µl 30 µl
Typical MRD Neat – 1 : 10 Neat – 1 : 10 Neat – 1 : 10 Neat – 1 : 30 Neat – 1 : 10 Neat – 1 : 10
Typical
sensitivity
ng ml−1 –
µg ml−1
fg ml−1 – pg ml−1 pg ml−1 – ng ml−1 fg ml−1 –
ng ml−1
pg ml−1 – ng ml−1 pg ml−1 –
ng ml−1
Dynamic range >2 logs >4 logs >2–3 logs >4–5 logs >4 logs >3–4 logs
Reference 42, 46, 95 56, 57, 102 55, 97–100 49, 50, 57,
66
46, 103 91, 104
a Typical total per-well/vial volume at assay’s sample dilution.
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reduction of antibody-coupled tris(bipyridyl)ruthenium(II)
complexes on electrode surfaces which leads to photon
excitation upon regeneration with tripropylamine (Fig. 4b).
ECL sensitivities are usually slightly better than those of con-
ventional ELISA. The main advantage of this technology stems
from its potential for multiplexed analysis of targets in un-
purified sample materials without the need of extensive
washing.118 Similar as in ELISA, specificity of critical assay
reagents, in particular antibodies, and interference from
matrix components with the analyte binding event drastically
limit multiplexing capacity. With commercial vendors and con-
tract research organizations (CRO) available, ECL is routinely
used in pharmaceutical large molecule drug development
support. Case studies range from oncology,119 neurodegenera-
tive disorders120 and metabolic diseases121 to autoimmune
defects.122 Moreover, ECL is widely used in screening for
unwanted immunogenicity of Biologics.119,123 Some time ago,
ECL support in drug development trials was hindered by the
acquisition of the only commercial vendor which blocked
the access to this technology by the acquiring party.124
These problems are nowadays solved and ECL is certainly
a good alternative in cases where classical ELISA reaches
it’s limits.
3.3 Immuno-PCR
Since the early nineteen-eighties, the polymerase chain reac-
tion (PCR)43,125 has become the major tool in molecular
biology and the related life-sciences owing to the extremely
sensitive and eﬃcient amplification of nucleic acid tem-
plates.126 This level of sensitivity, nowadays routinely used for
detection of even single molecular targets,127 has long been
inaccessible for LBA technologies. To overcome these limit-
ations, the concept of Immuno-PCR (IPCR, Fig. 4c), combining
ELISA-type LBA technologies with the exponential signal
amplification power of PCR, was developed in 1992.128 In con-
trast to the antibody–enzyme conjugates used in ELISA, the
key reagents in IPCR are antibody–DNA conjugates wherein a
DNA-marker is linked to the detection antibody. DNA-polymer-
ase is added subsequently as part of a reaction master-mix,
which allows for quantitative measurement of the DNA-marker
(and thus the analyte–antibody immunocomplex) by quantitat-
ive PCR (qPCR). During the last two decades, an increasing
number of DNA modifying enzymes and techniques for
sequence specific manipulations of nucleic acids have led to
additional DNA-based LBA technologies. Because these devel-
opments were typically conducted as proof-of-concept studies
and they have been surveyed previously,45,47,51,52,129 we will
here focus on the most important features of IPCR and illus-
trate the state-of-the-art of this LBA technology on the basis of
case studies in the area of pharmaceutical drug development
programs.
Even though amplification of nucleic acid molecules allows
one for detection of theoretically single target molecules, the
immune–aﬃnity coupling steps between DNA-labeled detector
molecules and analyte significantly increases the number of
target molecules needed for specific signal amplification. Due
to the steady-state on/oﬀ kinetic nature of antibody–antigen
binding, a level of approx. 1000 analyte molecules in a typical
immunoassay volume of 100 µl can be considered as theore-
tical detection limit for immunoassays.130–132 The survey of
LODs (limit of detection) reported in relevant IPCR publi-
cations confirmed this theoretical considerations.50 Indeed, a
broad range of IPCR case studies demonstrated LODs close to
the theoretical detection limit of LBAs, down to a few 1000
analyte molecules or even below.45–47,50,129 Applying these
numbers onto a typical protein target of about 50–100 kD in
size, this LOD translates into sub-picogramm amounts of
target proteins, which is considered suﬃcient for quantifi-
cation of low abundant biomarkers or free bioactive markers
traced in supportive (pre)clinical LBA support studies where
the biomarker is the actual drug target.49
Various modifications of the initial IPCR protocol128 have
been reported, many of which have led to a significant increase
in the analytical sensitivity. In some academic and exploratory
applications even an extreme enhancement of more than
100 000-fold in comparison to ELISA LODs was reported.133–136
Despite these impressive numbers, IPCR assays have long
been considered as cumbersome, hard to develop, and lacking
the robustness required for bioanalytical sample testing
support in pharmaceutical drug development. Technical
issues concerned the availability of appropriate microplate
materials which are thermostable and have high protein
binding capacity,49 as well as the need for careful handling of
liquids and avoidance of plate transfer steps to minimize
cross-contamination.137–139 These issues also apply for alter-
nate approaches, such as bead-based IPCR assays49,91,140,141 or
chemically activated glass surfaces designed for automated
processing.142 Therefore, similar as for SMC56 or ECL,99
specialized laboratory equipment and matching kits of
reagents and consumables are mandatory to take full advan-
tage of the power of this LBA technique.126 For instance,
highly sensitive quantitative Immuno-PCR (qIPCR)66 assays,
commercially available since the early 2000 years, contain
pre-synthesized antibody–DNA conjugates. These are the
key reagents for IPCR because they eliminate cumbersome
syntheses or multi-step on-surface assembly of immuno-
complexes.49,50,91,143–145 The latter is particularly disadvanta-
geous for assay performance because each coupling step in the
LBA protocol represents a potential error source132,146,147 and
leads to decrease in assay performance.64 These developments
led to reduction of LLOQ for macromolecules in pharmaco-
kinetic and pharmacodynamic pre-clinical81 and clinical
studies16,82,148,149 down to several 1000 molecules along with
a wide standard-curve range of up to six orders of
magnitude.45,47
As an example, the advantages of pre-conjugated reagents
over sequential protocols have clearly been demonstrated in a
study concerning detection of human interleukin 6 (IL-6).66
Indirect sandwich assay and sequential incubation resulted in
an LOD of 10 pg ml−1 IL-6 in human serum, demonstrating an
approx. 100-fold improvement over conventional ELISA. In
comparison, the use of IL-6 specific pre-conjugated reagents
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enabled another 100-fold gain in sensitivity with an LOD of
100 fg ml−1 corresponding to an approx. 10 000-fold advance
as compared to ELISA.66 Commercial IPCR technology is nowa-
days available at contract research organizations (CRO)150,151
for custom assay development83,84,151–153 as well as bioanalyti-
cal services under various regulatory regimes up to full good
laboratory practice (GLP) standards.57,150,154 This not only
enables pre-clinical toxicology studies to support investiga-
tional new drug (IND) programs but also to realize fully vali-
dated IPCR protocols for sample testing support under GLP
regime. It is therefore not surprising that this technology has
found its way into routine application. Exemplary case studies
will be discussed in the following.
Mucosal vaccination. IPCR has a proven track record in the
quantification of viral loads enabling valuable information on
the acute status of a viral infection. Examples include HIV,155
rotavirus78 and norovirus,156 wherein highly complex and chal-
lenging matrices like food homogenate or patient stool under-
lined the method’s high matrix tolerance. Likewise, very low
numbers of pathogens were detected in large sample volumes,
e.g., to monitor bacterial contamination of water157 and
food.158–162 Moreover, single-cell sensitivity was demonstrated
in pre-implantation diagnostics of histocompatibility complex-
presenting blastocysts.163,164 Based on this capability for the
high-sensitivity quantification of biomarkers, IPCR has been
used in the development of novel vaccination strategies.165–167
Virosomes are artificial virus particles presenting the actual
vaccine structure but lacking the viral genome. Virosome vacci-
nation against mucosal transfected diseases, such as HIV, was
recently established by aid of IPCR as supportive analytical
technique in the course of an initial phase-I clinical trial.82,83
In this study, anti-vaccine specific IgA and IgG antibodies as
well as total IgA and IgG response needed to be quantified in
mucosal and serum samples (Fig. 6). Particular challenges
included the approx. 100-fold lower antibody concentrations in
mucosal tissue as compared to blood as well as strongly
limited mucosal material owing to the complex mucosal
sampling procedures. Moreover, it was diﬃcult to identify anti-
bodies for specific diﬀerentiation of the four immunoglobulin
targets in the presence of cross-reactive alternate immuno-
globulin subspecies present in the samples. The use of high
sample dilution of up to 1 : 1 000 000 solved these problems.
Four antibody concentrations could be quantified in parallel
from the limited mucosal material and serum samples, using
the polyplexing strategy. Hence, this case study underlines a
general and highly important feature of the IPCR technology:
although multiplexing of IPCR assays has proven feas-
ible,49,65,68,168,169 high sample dilution along with polyplexing
leads to better results because the employed antibodies cannot
cross-react with each other.
Biomarker quantification. Quantification of biomarkers for
exploratory purposes or bioanalytical support in pharmaco-
dynamics (PD)170 represents an important field where high-
sensitivity IPCR assays are applied.49,50 For example, relevant
biomarkers for neurodegenerative disorders like Alzheimer’s
and Parkinson’s disease or vCJD typically are found in the
brain at very low concentration in early development phases of
these diseases.171 The analysis of sample materials from inva-
sive procedures like lumbar puncture or cerebrospinal fluid
(CSF) drawn directly from the brain for in vivo/ante-mortem
detection requires a bioanalytical method with minimal
sample consumption and matrix interference and yet an excel-
lent sensitivity.172 Moreover, detection of indicative bio-
markers in the periphery, such as blood, would be highly
attractive due to easier accessibility of samples, but biomarker
concentrations in blood are drastically lower than in the
central nervous system.173 Owing to it’s extraordinary sensi-
tivity, IPCR has successfully been applied for quantification of
neurodegenerative disease biomarkers in various matrices.
One case study concerned the analysis of a phosphorylated
TAU protein biomarker associated with Alzheimer’s disease,
pTAU-Thr181,
174,175 In the course of a pre-clinical study
support, this biomarker was quantified in murine CSF micro-
samples because the total CSF volume available from a single
sacrificed mouse is only approximately 5 µl.176 IPCR provided
Fig. 6 A.) Scheme on polyplexing strategy for IPCR sample testing to
support a clinical phase I Virosome HIV vaccination trial in young
healthy women.82,83 High sample dilution in IPCR allows to divide a
single mucosal or serum sample for separate quantiﬁcation of Virosome
speciﬁc IgA and IgG response in addition to total IgA and IgG levels. This
allows for normalization of speciﬁc response for variability in mucosal
sampling and overall immune status. b.) High (+) and low (−) dosed vac-
cination leads to speciﬁc IgA and IgG response, clearly detectable over
the corresponding placebo (o) groups. The solid lines represent the
median from high (+) and low (−) dosed antibody response. No
unspeciﬁc cross reactivity in testing for speciﬁc vs. total antibody was
found, despite the fact that a greater than 1000-fold excess of total over
speciﬁc antibody was present in the samples.83
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a meaningful sensitivity of around 1 pg ml−1 LLOQ at 1 µl
sample requirement for testing in duplicate. Other examples
of IPCR for biomarker quantification from microsample
materials obtained by non- or less-invasive procedures (e.g. fin-
gertip/earlap blood vs. venous blood, or venous blood vs.
biopsy) include various metabolic intermediates.49,50 For
instance, the pharmacological relevant biomarkers myostatin
propeptide and follistatin, correlated to fat and muscle metab-
olism,177,178 were quantified in earlap blood-derived serum
and muscle biopsy human samples to identify characteristic
patterns indicative for doping eﬀects in sports.169
Cytokines represent an important class of pharmaceutically
relevant biomarkers because not only they are often used to
monitor eﬀects of therapeutic drugs but also because they are
often the actual drug target for treatment of disease indi-
cations, such as autoimmune disorders. Examples for IPCR-
based analyses of such biomarkers important for cell growth,
diﬀerentiation, and immunomodulation include IL-6,66
IL-18179 and TNF.139,180–182 Another member of the cytokine
panel is human Granulocyte Macrophage Colony Stimulating
Factor (GM-CSF),144,183,184 which is secreted by various cell-
types of the immune system and, among other activities,
believed to play a major role in the development of auto-
immune inflammatory diseases like multiple sclerosis, and
rheumatoid arthritis, and respiratory defects like atopic
asthma.143 Therefore, GM-CSF is often used as indicative bio-
marker for the development of novel drug candidates,143,144
and recombinant GM-CSF is applied as immune modulating
drug.145,185 Since endogenous GM-CSF levels are usually low,
ultra-sensitive bioanalytical support was enabled by a validated
IPCR assay, which enabled the quantification of changes in
endogenous GM-CSF concentrations in the range of 0.01–200
pg ml−1, with an LLOQ of 11 fg ml−1.153 This assay indicated
that endogenous levels of human GM-CSF were typically
between 0.06–0.4 pg ml−1 within the healthy control popu-
lation, while asthma and multiple sclerosis patients have elev-
ated levels in the range of 1.0–3.4 pg ml−1 and 1.6–4.4 pg ml−1,
respectively. Notably, all these examples confirmed the broad
dynamic range of IPCR assays, spanning at least four orders of
magnitude.
Drug quantification and pharmacokinetics. ELISA assays
are often suﬃcient for sample testing to determine drug con-
centration data in pharmacokinetic (PK) studies,186 because
the drug is usually administered in relatively high dosage,
leading to intracorporeal concentrations in the ng ml−1 range
and above.187,188 However, determination of PK profiles for
some drug candidates, like highly cytostatic drugs77,149 or
potent toxin derivates189 require low dosage and thus ultra-
sensitive bioanalytical support. As an example, the picomolar
potency of ShK-186,190 a venom peptide derived from sea
anemone, demanded ultra-sensitive bioanalytical sample
testing support to characterize the pharmacokinetic profile of
the drug in a clinical phase-I trial.191 This highly toxic peptide
is a specific and potent inhibitor of the Kv1.3 ion-channel and
suppresses activation of TEM cells leading to a reduction of
inflammation and tissue damage. Hence, ShK-186 is under
development for treatment of various autoimmune diseases. A
highly sensitive IPCR assay was developed and validated in
accordance to relevant industry guidelines to quantify low pg
ml−1 concentrations of ShK-186 for clinical sample testing
support.152 Previously evaluated technologies indicated very
low PK concentrations in animal toxicology studies, even with
administered dosages of up to 500-fold above the eﬀective
dose. Therefore, phase-I trial support required quantification
of concentrations of down to 250-fold lower than the concen-
trations administered in the toxicology studies. The developed
IPCR assay oﬀered a more than 135- or 650-fold increased sen-
sitivity as compared to the corresponding LC-MS or ELISA
assays, respectively. It was therefore suitable for supporting the
clinical trial, which included single ascending doses in
healthy subjects with four dosing cohorts. In the blinded
sample panel it was possible to correctly identify the unknown
placebo individuals through specific PK profiles, revealing
details like the maximum drug concentration recorded
(Cmax),
192 the time interval to reach maximum drug concen-
tration (Tmax),
192 andspecific profiles of drug wash-out phases.
This not only allowed the prediction of the therapeutic range
but also shed light on previously observed but not well under-
stood PD eﬀects. Connection with PK data then enabled mod-
elling PK/PD correlation to establish optimized dosing
protocols for future trials.152 This case study nicely demon-
strates how ultra-sensitive PK support fosters the development
of novel extremely potent drug classes, such as toxin-like
peptides.
IPCR has also been employed to compensate for strong
matrix eﬀects or the presence of endogenous compounds,
which interfere with the quantification of the drug. Many
biotherapeutic drug candidates, which possess structurally
homologous domains to the endogenous protein5,8,9 or fusion-
proteins193 are prone to competitive interaction with their
endogenous binding partners, present in clinical study
samples. This leads to a decrease in eﬀectively detectable drug
concentration due to limited binding capacity of the capture
coated surface in ELISA-type LBA, and thus calls for ultra-sen-
sitive techniques. In a recently published case study, IPCR was
employed for PK sample testing of a novel biotherapeutic Fc-
fusion protein,193 under development as a drug for a novel
long-acting replacement therapy.84 Bioanalytical support of
phase-II/III studies for this replacement therapy required an
LBA with minimal interference of the endogenous counterpart
and circulating IgG. It was found that an IPCR assay had
suﬃcient analytical sensitivity despite the high MRD of 1 : 100
of the clinical sample, chosen to minimize interference from
endogenous binding partners. The assay was fully validated to
meet clinical sample testing support requirements and pro-
vided a dynamic range of 20–9000 ng ml−1 of the recombinant
Fc drug with no significant interference from a greater than
300 000-fold excess of endogenous IgG as well as the endo-
genous specific binding partner present in >250-fold excess.
Assay parameters met validation criteria in human plasma, either
depleted or deficient of the endogenous counterpart, as well
as normal human plasma, using depleted human plasma pool
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as standard-curve matrix. Dilution integrity and linearity was
confirmed, thereby allowing for further sample dilution, which
led to the expansion of the detection range to up to 50 000 ng
ml−1. Since this method was successfully used for bioanalytical
support of a clinical phase-II/III multi-center study, this case
study impressively demonstrates the utility of IPCR for PK
support of testing novel pharmaceutical large molecule drugs.
The testing for unwanted immune response of patients
exposed to Biologics is a task related to PK assessment of this
class of drugs. Immunogenicity of the drug may have various
consequences ranging from aﬀecting the PK profile over mild
or severe adverse reactions up to an anaphylactic shock.33 The
use of IPCR for immunogenicity testing has been described to
reveal a good tolerance towards the presence of circulating
drug in the sample, which blocks the anti-drug antibody (ADA)
from binding to the drug.85 To this end, the drug is employed
as binding reagent in the so called bridging assay format. In
this example, the sensitivity of IPCR was exploited to detect
free ADA present in the sample despite a significant excess of
the interfering drug, thereby demonstrating an optimized drug
tolerance of this assay as compared to ELISA or ECL.194,195
Depending on the sensitivity for the ADA, binding aﬃnity
of the employed ADA standard to the drug and other study
specifics, IPCR assays can be designed with195 or without194
acid dissociation steps, routinely employed in alternate LBA
techniques to liberate ADA from the circulating drug.
3.4 Proximity ligation
Similar as in IPCR, a number of additional commercially avail-
able LBA technologies make use of nucleic acids as markers
for enzymatic signal amplification and read-out. While the
majority of these LBA employs capture reagents on solid phase
supports either in microtiterplates or in suspension assays
using micro- and nanoscaled beads, homogenous assay
formats can also be used. The latter have the advantage of
more eﬃcient analyte binding because binding is less aﬀected
by mass transport phenomena at the interphase and thus
binding equilibria are reached faster than in heterogeneous
assays. Since no washing steps can be implemented in homo-
genous assays, they also come along with shorter processing
times. Primary examples of sensitive homogenous solution
assays are proximity ligation assays (PLA),46,196,197 which have
been reviewed recently.51 In PLA, two specific antibodies
directed against the target are labelled with individual oligo-
nucleotides. Coincident binding of the two antibodies enables
enzymatic ligation of the two oligonucleotides in the presence
of a supporting third DNA oligonucleotide to generate a DNA
template molecule for subsequent PCR or rolling circle ampli-
fication (RCA) (Fig. 7). The Nucleic Acid Detection Immuno-
Assay (NADIA)198 technique, a variant of PLA also referred to
as proximity extension assay (PEA),199 omits enzymatic ligation
of the two marker-oligomers and, instead, uses self-priming
overhang sequences of the two detector oligomers to enable
primer extension with a polymerase leading to formation of a
double-stranded template for subsequent PCR signal amplifi-
cation. Usually, either polyclonal antibodies or two mono-
clonal antibodies binding diﬀerent epitopes of the analyte
are used to realize liquid phase binding in PLA or
NADIA.197,200–202 These technologies have been proven
especially useful for quantitative assessment of ligand/receptor
interactions and conformatorial changes in analyte struc-
ture.196,203 Spatial proximity of epitopes present in either one
or else interacting pharmaceutically relevant biomolecules can
be quantified through signal amplification of the assembled
DNA-marker.197,198,201
PLA critically depends on the selection of specific antibody
pairs, required to simultaneously bind the analyte in a way
that enables enzymatic ligation or primer extension. A poly-
clonal antibody population directed against a given antigen can
be used for this purpose, which is split into two fractions each
including binders for diﬀerent epitopes which are labelled
with one of the two DNA marker strands.204 Even though this
strategy proved feasible for the detection of protein biomarkers
with femtomolar sensitivity,204 the variability of polyclonal
antibody preparations brings the drawback of limited long-
term availability of critical assay reagents in routine appli-
cations. In particular, even slight variations in polyclonal anti-
body properties can strongly aﬀect assay reproducibility in
support of larger clinical trials. The concept of solid-phase
PLA (spPLA)205,206 using an additional capture antibody
immobilized on magnetic particles along with the two oligo-
Fig. 7 Schematic overview on proximity assays. Separate DNA-tags of
at least two diﬀerent antibodies binding to epitopes in close proximity
are used to generate a speciﬁc signal for the immune-binding event.
Homogenous assay formats: (A) Proximity Ligation Assay (PLA). The full-
length DNA template for downstream signal ampliﬁcation by PCR is
generated by ligation of two DNA oligonucleotides in the presence of a
short DNA connector sequence (“splint”). (B) Nucleic Acid Detection
ImmunoAssay (NADIA)/Proximity Extension Assay (PEA). Two self-
priming overhand sequences enable primer extension by DNA-polymer-
ase to enable subsequent signal ampliﬁcation by PCR. C) Semi-homo-
genous solid phase Proximity Ligation Assay (spPLA). The two DNA-
tagged detection antibodies are supplemented with a third capture anti-
body, immobilized on the surface of a magnetic bead. In comparison to
homogenous assay formats, this approach can lead to increased assay
speciﬁcity and selectivity due to the third independent antibody binding
event and the possibility for additional washing and sample processing
steps.
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nucleotide-labeled antibodies for signal generation (PLA
probes) gives rise to eﬀectively screen for suitable antibody
combinations. The three independent binding events even
more increase the specificity of detection. Furthermore, spPLA
allows one to include washing steps for removal of excess PLA
probes.205 In an impressive proof-of-concept study, a variant of
spPLA, dubbed ProteinSeq, which employed PCR-based ampli-
fication along with next generation sequencing (NGS)207–209 as
read-out, was used for highly multiplexed protein biomarker
screening to simultaneously detect 35 human biomarkers in a
volume of only 5 µl of plasma sample.103 Interestingly, no
molecular weight-dependent bias in assay performance was
reported for targets down to 17 kDa, even though three inde-
pendent epitope-binding events are necessary to obtain
signals.
Another key requirement of pharmaceutical testing support
concerns assay precision, which has been reported as unaccep-
tably high for PLA in the case of real-time PCR readout.205 So
called “digital PLA” has been developed to optimize PLA assay
precision.210 It combines single molecule counting, referred to
as amplified single molecule detection (ASMD)211 and
spPLA,205,206 and improved precision has been claimed for
this rather complex procedure although no specific data on
improved intra- or inter-assay precision were reported.210
Nonetheless, PLA and related techniques certainly hold great
potential for use in pharmaceutically relevant application
fields like oncology,212 immunology,213 neurodegenerative dis-
orders,214 virology,215 or stem cell research.216 Examples from
these fields include analysis of gene expression,217–221 the
study of post-translational modifications or gene spli-
cing,197,222,223 the monitoring of conformational changes in
protein structure, or quantification of protein–protein
interactions.196,201,202,224–227
In a phase-I clinical gene therapy trial published
recently,228 PLA was used to analyze changes in tumor suppres-
sor gene (TUSC2) protein expression in biopsy samples of
three lung cancer patients. Lack of TUSC2 activity is correlated
with development of lung cancer and TUSC2 expression
plasmid-containing nanoparticles were administered intra-
venously to reactivate TUSC2 activity in primary and metastatic
tumors. Rabbit polyclonal antibodies directed towards the
amino-terminal sequence of the TUSC2 was used and a 10–25-
fold increase over background levels prior to treatment could
be demonstrated with the PLA assay. Another case study has
also been reported where PLA has been used in support of
gene therapy using a modified adenovirus.229
Owing to the afore mentioned possibilities to combine sen-
sitivity with specificity in highly multiplexed protein detection,
the most promising pharmaceutically relevant application of
PLA and related techniques appears to concern the identifi-
cation and validation of novel biomarkers for use in transla-
tional medicine.230 Numerous reports on highly multiplexed
biomarker screening,200,204,231,232 especially in human blood
proteome199,205,233,234 have been published in the last 15
years.235 Despite this vast number of biomarker candidates, on
average, less than two per year were actually approved by the
FDA.236 This underlines the relevance of PLA, spPLA and
related techniques to overcome and extend the limitations of
conventional multiplex immunoassays, which often do not
provide the necessary specificity to unambiguously identify a
relevant biomarker. Moreover a significant increase in capacity
from a handful of targets in conventional LBAs to hundreds or
even several thousands of targets is in sight by using homo-
genous or “ProteinSeq”103 PLA-type approaches. While con-
ventional immunoassays are prone to wrong positives in the
identification of lead biomarkers due to cross reactivity of the
used antibodies, this eﬀect seems to be controllable with PLA-
type techniques.231,235 This would hold great potential for
translational medicine, in the identification and exploitation
of pharmaceutical relevant molecular interactions.237
3.5 Nanoparticle-based methods
The so-called “Bio-Barcode” approach,91,104,136,238–240 takes
advantage of micro- and nanoparticles. Capture antibody-
coated magnetic microparticles and gold nanoparticles func-
tionalized with both detector antibody and marker-DNA mole-
cules241 are used for detection of protein targets.46,47 As
schematically illustrated in Fig. 8, the capture antibody-coated
magnetic microbeads are used for concentration of soluble
antigens on the bead’s surface and subsequently, gold
nanoparticles242–244 bearing amplifyable DNA marker mole-
cules (the bio-barcodes) and analyte-specific detection anti-
bodies are allowed to bind to the analyte-containing
Fig. 8 Bio-Barcode technology. Magnetic microparticles containing
capture antibodies are used for enrichment of target (red sphere) and,
following magnetoseparation and washing, gold nanoparticles functio-
nalized with detection antibodies and DNA reporter molecules, the
“Bio-Barcodes”, are bound. Subsequent to magnetoseparation and
washing, immunocomplexes are dissociated and detection of DNA
reporters is achieved by hybridization or PCR.
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microparticles. Immunocomplexes are purified by magnetic
separation and the bio-barcode sequence is detected by either
hybridization239,240,245 or qPCR.91,246 Although no case studies
using “Bio-Barcode” approaches for PK sample testing support
are available, pharmaceutically relevant case studies range from
quantification of toxins,247,248 food-born249 and other human
pathogens250–252 over HIV253,254 and other viruses255,256 to
human biomarkers like cytokines,240 PSA,257 thrombin,258 or
cytochrome c.259,260
4. Conclusions
The increasing developments of “Biologics”, novel protein
therapeutics for treatment of complex human disease indi-
cations, which are out of reach of traditional small molecule
drugs, has led to the emergence of novel ligand binding assay
(LBA) tools to meet the challenges in the corresponding bio-
analytical sample testing within pre-clinical, clinical and even
post-marketing studies. Quantification of protein therapeutics
or biomarker levels in clinical samples is extremely important
for diagnosis and prognosis of many diseases, optimization of
dosages or evaluation of drug eﬃcacy. Since the determination
of drug or biomarker concentrations directly at the site of their
action (e.g., organ tissue) is often not possible, serological
samples, serum or plasma, are used as surrogate matrix in the
majority of clinical studies. Therefore, circulating analyte con-
centrations can be very low. In addition, endogenous levels of
relevant biomarkers are frequently below detection limits of
conventional ELISA techniques, which have been the tra-
ditional workhorse in immunoanalytics and can still be con-
sidered the gold standard. Consequently, immunoassays have
constantly been improved in performance regarding their sen-
sitivity and dynamic detection range. The elaboration of
alternative signal amplification methods, in particular electro-
chemiluminescence, nucleic-acid tags enabling PCR read-out,
or bead-based methods, even coupled with single molecule
detection, has led to improved immunoassay sensitivities by
several orders of magnitude. The emerging LBA technologies
discussed here represent the current state-of-the-art in ultra-
sensitive methods for pharmaceutical drug testing support.
The survey of case studies employing either one of these
methods suggests that no one-method-suits-all-applications is
currently available because the diﬀerent LBA technologies have
their specific advantages to meet the needs of a given study.
For instance, technologies with limited or no signal amplifica-
tion, like single molecule counting, have the advantage that
signal read-out cannot be biased by any kind of enzymatic
signal amplification, which might be influenced by matrix
components, for example phosphatase or peroxidase inhibi-
tors. Proximity-based assays, like PLA, can be employed to
almost entirely suppress non-specific signals, even in highly
multiplexed assay formats. This provides a well suited platform
for biomarker identification or validation, which may poten-
tially revolutionize the identification and selection of bio-
markers or lead compounds for drug development. However,
these platforms do not always display highest sensitivity,
which is typically needed when it comes to downstream
analyte quantification, in particular, from small sample
volumes. In these cases, PCR-based LBA platforms, such as
IPCR, seem to be the best choice because of their enormous
strength in signal amplification. This brings with it an excel-
lent tolerance for high sample dilution ratios, which even
allow for improvement of assay sensitivities. Highest amplifica-
tion power sets the basis for successful immunoassay sample
testing in so-called microsampling88,89 studies, where very
small sample volumes are available due to time-course studies
in individual, small animal models or because sampling stress
to patients needs to be minimized. For example, this is the
case in Dried Blood Spot (DBS)87,261,262 sampling studies,
which allow patients to collect minimal invasive blood
samples on specific filter paper at their homes rather than
undertaking venous blood sampling during frequent hospital
visits. In general, strong signal amplification opens the door to
flexible assay adaptation by sample dilution protocols to meet
the requirements when the bioanalytical sample testing
support has to progress with the drug development trial. The
here discussed ultra-sensitive LBA platforms provide a sound
basis for further coevolution along with the progression of
lead compounds in the development of modern drugs to
improve the quality of patients lives.
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